CHMP give positive opinion for Almirall and Sun Pharma’s plaque psoriasis treatment

Almirall, S.A. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has issued a positive opinion for the regulatory approval of tildrakizumab, an investigational humanised, high-affinity IL-23p19 monoclonal antibody for adults with moderate-to-severe chronic plaque psoriasis. Tildrakizumab is an innovative biological drug due to its specific mechanism of action.

Continue Reading

Government confirms that boys in England will receive HPV jab

Boys in England will be vaccinated against the human papilloma virus in line with recent recommendations from the Joint Committee on Vaccination and Immunisation (JCVI). The vaccine will protects men from HPV-related diseases, which include oral, throat, penile and anal cancer. Whilst also helping to reduce the overall number of cervical cancers in women through

Continue Reading

NICE approves Keytruda, MSD’s lung cancer drug, to be used as routine treatment on the NHS

A green light has been given for lung cancer drug Keytruda by NICE for the treatment for certain patients in England. Merck, Sharp, and Dohme (MSD)’s Keytruda will be available for those with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC), where tumours have specific protein and genetic markers. Keytruda is the first treatment

Continue Reading

Pfizer to start testing respiratory syncytial virus in healthy adults

Pfizer has begun an early stage trial of an experimental vaccine against respiratory syncytial virus (RSV) in healthy adult volunteers. Pfizer is aiming to develop the vaccine for populations at highest risk of the respiratory infection, primarily infants through maternal immunisation and older adults through direct vaccination. The Phase I/II, randomised, placebo-controlled, observer-blind, dose-ranging study

Continue Reading